DE69920487D1 - Tau als marker für frühe schäden des zentralen nervensystems - Google Patents

Tau als marker für frühe schäden des zentralen nervensystems

Info

Publication number
DE69920487D1
DE69920487D1 DE69920487T DE69920487T DE69920487D1 DE 69920487 D1 DE69920487 D1 DE 69920487D1 DE 69920487 T DE69920487 T DE 69920487T DE 69920487 T DE69920487 T DE 69920487T DE 69920487 D1 DE69920487 D1 DE 69920487D1
Authority
DE
Germany
Prior art keywords
dew
marker
cns
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69920487T
Other languages
English (en)
Other versions
DE69920487T2 (de
Inventor
Frank Hulstaert
Eugeen Vanmechelen
Hugo Vanderstichele
De Voorde Andre Van
Gool Stefaan Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Innogenetics NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA
Application granted granted Critical
Publication of DE69920487D1 publication Critical patent/DE69920487D1/de
Publication of DE69920487T2 publication Critical patent/DE69920487T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Devices That Are Associated With Refrigeration Equipment (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
DE69920487T 1998-09-08 1999-09-07 Tau als marker für frühe schäden des zentralen nervensystems Expired - Lifetime DE69920487T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98870190 1998-09-08
EP98870190 1998-09-08
PCT/EP1999/006592 WO2000014546A1 (en) 1998-09-08 1999-09-07 Tau as a marker for early cns damage

Publications (2)

Publication Number Publication Date
DE69920487D1 true DE69920487D1 (de) 2004-10-28
DE69920487T2 DE69920487T2 (de) 2006-03-09

Family

ID=8237090

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69920487T Expired - Lifetime DE69920487T2 (de) 1998-09-08 1999-09-07 Tau als marker für frühe schäden des zentralen nervensystems

Country Status (11)

Country Link
EP (1) EP1112500B1 (de)
JP (1) JP4624559B2 (de)
CN (2) CN1325491A (de)
AT (1) ATE277353T1 (de)
AU (1) AU772151B2 (de)
BR (1) BR9913112A (de)
CA (1) CA2340433A1 (de)
DE (1) DE69920487T2 (de)
ES (1) ES2229817T3 (de)
HK (1) HK1040429B (de)
WO (1) WO2000014546A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60334460D1 (de) 2002-08-14 2010-11-18 Mitsubishi Chem Medience Corp Antikörper spezifisch für das tau-protein des zentralen nervensystems
EP2386864A1 (de) 2002-10-09 2011-11-16 DMI Biosciences, Inc. Diagnose und Uberwachung von Ischämie
EP2578692B1 (de) 2007-04-05 2016-06-08 The J. David Gladstone Institutes Mittel zur Reduktion der nervlichen Überreizung
NO2324360T3 (de) 2008-08-11 2018-06-30
EP2478360B1 (de) 2009-09-14 2018-06-27 Banyan Biomarkers, Inc. Autoantikörpermarker zur diagnose von traumatischen läsionen am gehirn
RU2449287C1 (ru) * 2011-03-17 2012-04-27 Государственное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации (ГОУ ВПО СибГМУ Минздравсоцразвития) Способ антенатального прогнозирования последствий перинатальных поражений нервной системы у детей
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
EP3838921A3 (de) 2012-07-03 2021-09-01 Washington University Anti-tau-antikörper
KR101582387B1 (ko) * 2013-12-12 2016-01-05 서울대학교산학협력단 뇌전이암 원인종양 진단용 조성물 및 그의 용도
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
RU2568914C1 (ru) * 2014-07-31 2015-11-20 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский институт акушерства и педиатрии" Министерства здравоохранения Российской Федерации Способ прогнозирования перинатального поражения цнс у недоношенных новорожденных
WO2018081649A1 (en) 2016-10-28 2018-05-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69220503T2 (de) * 1991-10-25 1998-02-05 Innogenetics Nv Monoklonale Antikörper gegen das mikrotubulusassoziierte Protein Tau.
EP0673418B1 (de) * 1992-12-14 1998-05-06 N.V. Innogenetics S.A. Monoklonale antikörper gegen das mikrotubulusassoziierte tauprotein,hybridomen, die diese antikörper sezernieren, antigenerkennung durch diese monoklonalen antikörper und deren verwendung
JPH06239899A (ja) * 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
DE69529906D1 (de) * 1994-07-29 2003-04-17 Innogenetics Nv Monoklonale antikörper gegen ein epitop einer gewissen unterklasse oder form von phosphoryliertem tau, hybridome die diese sezernieren,antigenerkennung durch diese antikörper und deren verwendung
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau

Also Published As

Publication number Publication date
DE69920487T2 (de) 2006-03-09
BR9913112A (pt) 2001-05-08
HK1040429B (zh) 2005-08-12
EP1112500A1 (de) 2001-07-04
WO2000014546A1 (en) 2000-03-16
ES2229817T3 (es) 2005-04-16
ATE277353T1 (de) 2004-10-15
CN1325491A (zh) 2001-12-05
AU772151B2 (en) 2004-04-08
AU5974699A (en) 2000-03-27
EP1112500B1 (de) 2004-09-22
CN101046476B (zh) 2013-04-10
HK1040429A1 (en) 2002-06-07
CN101046476A (zh) 2007-10-03
JP2002524740A (ja) 2002-08-06
CA2340433A1 (en) 2000-03-16
JP4624559B2 (ja) 2011-02-02

Similar Documents

Publication Publication Date Title
DE69920487D1 (de) Tau als marker für frühe schäden des zentralen nervensystems
ATE310955T1 (de) Zusammensetzungen und verfahren zum nachweis und zur behandlung von mit chemokinrezeptoren verbundenen krankheiten
WO2004052175A3 (en) Methods for rapid identification of pathogens in humans and animals
WO2004060278A3 (en) Methods for rapid identification of pathogens in humans and animals
DE50304023D1 (de) Diagnose von Myokardinfarkt und akutem Koronarsyndrom durch Kombination von Markern
DE60215339D1 (de) Spezifische detektionsmedien für staphylococcus aureus und identifizierungs- und/oder zaehlmethode unter verwendung besagter detektionsmedien
HK1073153A1 (en) Systems and methods for identifying organ transplant risk
WO2005020785A3 (en) Discovery of the microorganism that causes the human autoimmune disease, primary biliary cirrhosis
HK1092841A1 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and /or diabetes
ATE336591T1 (de) Nachweisverfahren für kurze sequenzvarianten
DE69713498D1 (de) Methode zum nachweis übertragbarer spongiformer enzephalopathien
ATE451475T1 (de) Verfahren und systeme zur diagnose von nicht das zentrale nervensystem (zns) betreffenden krankheiten in zns-proben
ATE360071T1 (de) Rezeptor für ein toxin aus bacillus anthracis
AU2003259222A1 (en) Method of diagnosing alzheimer's disease
ATE504833T1 (de) Verfahren zur bestimmung des phänotyps von zellen
WO2003038444A3 (en) Biomarkers of liver function
WO2004058051A3 (en) Androgen-regulated genes and uses for diagnosis, prognosis and treatment of prostate neoplastic conditions
WO2003087761A3 (en) Molecular profiling of disease and therapeutic response using phospho-specific antibodies
MXPA05008793A (es) Metodos para la prediccion de posibilidad de suicidio durante el tratamiento.
ATE366260T1 (de) Kalzium-aktivierte kaliumkanäle mit niedriger und mittlerer leitfähigkeit und ihre verwendungen.
ATE463562T1 (de) Lp-pla2-aktivitätstest mit hohem durchsatz
ATE432996T1 (de) Verfahren zur bestimmung des bodenzustands
DE60127901D1 (de) TCF-1 Nukleotidsequenzvariation
ATE253223T1 (de) Verfahren und materialien zur diagnose instabiler angina
WO2006044439A3 (en) Methods of identifying metastatic potential in cancer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition